Sitagliptin phosphate + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Reactive Hypoglycemia
Conditions
Reactive Hypoglycemia
Trial Timeline
Dec 1, 2008 → Mar 1, 2011
NCT ID
NCT00847080About Sitagliptin phosphate + Placebo
Sitagliptin phosphate + Placebo is a approved stage product being developed by Merck for Reactive Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00847080. Target conditions include Reactive Hypoglycemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00847080 | Approved | Completed |
Competing Products
2 competing products in Reactive Hypoglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution | Sumitomo Pharma | Phase 3 | 77 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |